Introduction
============

Constipation is a common problem that is often associated with other symptoms, including painful defecation, bloating, and abdominal pain.[@b1-jnm-22-031] Although current consensus criteria emphasize the distinction between functional constipation and constipation-predominant irritable bowel syndrome (IBS-C),[@b2-jnm-22-031] systematic evaluations have shown a substantial overlap between these disorders.[@b1-jnm-22-031],[@b3-jnm-22-031],[@b4-jnm-22-031] Thus, it is not surprising that the treatment approaches for either disorders overlap as well. After serious adverse events led to the withdrawal of several drugs targeting functional gastrointestinal diseases,[@b5-jnm-22-031]--[@b7-jnm-22-031] regulatory agencies in the United States have put forth more stringent criteria for the approval and post-marketing surveillance of novel medications.[@b8-jnm-22-031] As a consequence, recent clinical trials have focused on patient-reported outcomes and the perceived adequacy of responses, such as the subjective satisfaction with bowel movements and detailed pain ratings. Considering the defining role of pain and discomfort in IBS-C, a paradigm is evolving, which first examines efficacy in patients with chronic constipation, followed by trials in patients with IBS-C, which require more comprehensive assessments that demonstrate improvement beyond changes in bowel patterns.[@b9-jnm-22-031]--[@b13-jnm-22-031] The results of the newer studies demonstrated lower pain ratings during treatment and prompted speculations about specific analgesic effects of these agents, potentially differentiating them from more conventional laxatives, a feature that has been particularly highlighted in reviews and advertising campaigns.[@b14-jnm-22-031],[@b15-jnm-22-031] Based largely on their impact on abdominal pain, the recently introduced pro-secretory agents (lubiprostone and linaclotide) were approved in the United States not only for the treatment of chronic constipation, but also specifically for the management of IBS-C, with marketing campaigns emphasizing their presumably unique benefits related to pain relief.[@b16-jnm-22-031]--[@b18-jnm-22-031] In the case of linaclotide, preclinical mechanistic studies supported the clinical data and suggested a possible specific analgesic effect. These investigations, which were previously also conducted with tegaserod, assessed acute responses to colorectal distension or stretch in normal subjects or animals.[@b19-jnm-22-031]--[@b21-jnm-22-031] Similar experiments did not reveal effects on sensory function with lubiprostone.[@b22-jnm-22-031] Despite the different impact on colorectal sensatory mechanisms,[@b19-jnm-22-031],[@b21-jnm-22-031]--[@b23-jnm-22-031] linaclotide, lubiprostone and tegaserod alleviated chronic pain ratings in IBS-C and constipation.[@b9-jnm-22-031]--[@b11-jnm-22-031],[@b24-jnm-22-031]--[@b26-jnm-22-031]

Interestingly, two studies compared the effects of tegaserod with polyethylene glycol (PEG), which acts as an osmotic laxative and should thus not directly affect sensory mechanisms or pain. However, the simple laxative was either superior to or demonstrated an equivalent effect to tegaserod.[@b27-jnm-22-031],[@b28-jnm-22-031] In addition, reducing bowel frequency in healthy volunteers with loperamide led to symptoms consistent with IBS-C.[@b29-jnm-22-031] These studies suggest that constipation is not exclusively defined by a low bowel frequency and/or the need for excessive straining due to hard bowel movements. Improving constipation may therefore also improve associated symptoms, such as discomfort and pain. Considering this potential association between constipation and abdominal discomfort, we hypothesized that pain relief should correlate with the laxative effects of these agents as a general phenomenon and may be largely independent of the specific mechanism of action of the agent. Thus, we performed a systematic review of clinical trials that included detailed assessments of both bowel patterns and abdominal discomfort in adults suffering from chronic constipation or IBS-C. This approach allowed us to use a meta-regression analysis to determine the relationship between these 2 clinical variables.

Materials and Methods
=====================

Search Strategy
---------------

We searched the "PubMed" and "Embase" databases for publications between 1974 and October 2014 using the terms "constipation" and "pain," along with filter settings for "clinical trials," "humans," and articles published in "English." For our "Embase" search, we also further restricted the search to "fully published" articles. All of the retrieved titles were independently reviewed to determine whether the focus was on treatment of chronic constipation or IBS-C in adults, and whether original data were presented. Titles meeting these criteria were then included in the next level of review with an examination of abstracts to assess study design, clinical variables measured, and target population. Finally, we retrieved and reviewed full-length articles that potentially met inclusion criteria based on the information presented in the abstract. Two of the authors (K.B. and S.N.) conducted the review independently, and reconciled discrepancies by involving a third reviewer (D.J.L.).

Data Abstraction and Inclusion Criteria
---------------------------------------

We recorded trial design and analytic approach, abstracting data based on the "intention to treat" rather than "per protocol" analyses if both were provided. We abstracted data including sample size, type of investigational and control interventions, treatment allocation, dropout rates, and trial duration (only studies measuring a treatment for 4 weeks or more were included). Considering our underlying hypothesis, we recorded both baseline assessments of bowel movement frequency and abdominal pain intensity scores, and the results at the conclusion of the active treatment phase of the trial. If more than one measure of bowel patterns was provided, we selected the number of weekly defecations. If treatment-induced changes in bowel patterns were not described in sufficient detail, we then considered dichotomized response rates based on predefined changes in bowel patterns as a secondary endpoint. Only patient-based ratings and reports were used.

Exclusion Criteria
------------------

Studies performed with children, patient cohorts with a disease duration of less than 3 months, patients with opioid-induced constipation, results describing only global ratings without specific information about bowel frequency or pain intensity, articles providing data expressed only as a median and/or range, and post-hoc analyses describing subgroups or treatment with open-label extensions of previously published trials were excluded.

Analytic Strategy
-----------------

We summarized bowel frequency as defecations per week and pain intensity ratings as key variables at baseline, and also determined treatment-induced changes at the end of the predefined trial duration. As reports relied on different scales, we abstracted the ratings of pain intensity, and normalized the mean and variance to a 5-point scale. We assessed these data for cohorts with constipation and/or IBS-C, and used the more conservative random effects meta-regression of the published data to determine if changes in bowel movement frequency predicted changes in pain intensity as the dependent outcome measure.[@b30-jnm-22-031] Considering the underlying hypothesis, we separately recorded effects of active treatments and placebo or sham controls, but did not compare the efficacy of these different treatments on key endpoints. As opposed to such a meta-analytic approach that assesses the differential impact of treatments on outcomes between groups or at distinct time points, we employed meta-regression techniques that correlate changes in a pre-defined covariate with the outcome of interest.[@b31-jnm-22-031] While such an approach is similar to conventional regression analyses, meta-regression does not correlate individual data points, but uses aggregate data, which require appropriate measures of variance to limit errors associated with this approach (see exclusion criteria). Unless indicated otherwise, data are given as mean with 95% confidence interval.

Results
=======

Using our initial search strategy, the "PubMed" search yielded 3737 publications, which dropped to 1032 when the predefined filter settings were applied ([Fig. 1](#f1-jnm-22-031){ref-type="fig"}). We then excluded 783 publications because the description given in the title clearly did not meet inclusion criteria. An additional 163 publications were rejected based on a review of abstracts. The remaining 87 articles were then reviewed in greater detail for potential inclusion. Of this number, 64 publications were not included in the analysis, primarily due to missing details on abdominal pain or bowel patterns, leaving a total of 23 studies.

The initial "Embase" search identified 6528 publications, with 6391 articles excluded based upon further filtering and review of the titles. An additional 42 publications were excluded based on a review of the abstracts. These articles included all but one of the previously identified publications from the "PubMed" search, and 4 additional studies ([Table 1](#t1-jnm-22-031){ref-type="table"}). The main exclusion criteria were insufficient details about bowel patterns or pain ratings, short trial duration, or a focus on pediatric patients ([Fig. 1](#f1-jnm-22-031){ref-type="fig"}). In addition to the publications described above, 13 studies used a predefined threshold for treatment response to dichotomize the data and report response rates for changes in bowel patterns ([Table 2](#t2-jnm-22-031){ref-type="table"}).

Of the articles included in the analysis, 16 focused on chronic constipation,[@b11-jnm-22-031],[@b24-jnm-22-031]--[@b26-jnm-22-031],[@b32-jnm-22-031]--[@b42-jnm-22-031] 11 enrolled patients with IBS-C,[@b27-jnm-22-031],[@b43-jnm-22-031]--[@b51-jnm-22-031] with one also including patients with mixed bowel patterns.[@b48-jnm-22-031] One study did not differentiate IBS-C from constipation.[@b52-jnm-22-031] Sample sizes varied between 7[@b38-jnm-22-031] and 1348,[@b25-jnm-22-031] exceeding 100 in 10 of the publications ([Table 1](#t1-jnm-22-031){ref-type="table"}). A study design using randomized allocation of 2 distinct groups to either an active or control intervention was used in 19 of the trials. The remaining seven publications described trials using a cross-over design[@b32-jnm-22-031],[@b40-jnm-22-031] or were unblinded cohort studies.[@b35-jnm-22-031],[@b37-jnm-22-031]--[@b39-jnm-22-031],[@b51-jnm-22-031] Five trials compared two active agents with each other,[@b27-jnm-22-031],[@b33-jnm-22-031],[@b35-jnm-22-031],[@b42-jnm-22-031],[@b52-jnm-22-031],[@b53-jnm-22-031] with the other trials using placebos as controls ([Table 1](#t1-jnm-22-031){ref-type="table"}). Most trials relied on medical, herbal, or dietary interventions, with only one trial describing the effect of biofeedback[@b35-jnm-22-031] and 2 studies reporting the effect of subtotal colectomy[@b39-jnm-22-031] or sacral nerve stimulation,[@b37-jnm-22-031] respectively.

Bowel Movement Frequency
------------------------

As expected from a target population of constipated patients enrolled in the published trials, baseline bowel movement (BM) frequencies were low, with a mean weekly BM frequency of 2.35 \[2.07--2.64\] ([Fig. 2A](#f2-jnm-22-031){ref-type="fig"}). The detailed definition of BM endpoints significantly affected the numeric results. Studies reporting simple mean weekly BMs demonstrated greater frequencies (2.87 \[2.56--3.19\]) compared with weekly *spontaneous* BM frequency (1.92 \[1.31--2.53\]) or "complete spontaneous" BM frequency (1.06 \[0.54--1.58\]; comparison between endpoints: Q = 35.9, *P* \< 0.001; [Fig. 2B](#f2-jnm-22-031){ref-type="fig"}). While the funnel plot did not suggest systematic skewing of results ([Fig. 2C](#f2-jnm-22-031){ref-type="fig"}), the intercept of Egger's regression indicated potential publication bias (intercept: 10.55 (SEM: 1.51; *P* \< 0.001).

Interventions increased weekly BM frequency in all cohorts by 2.17 \[1.88--2.47\] ([Fig. 3A](#f3-jnm-22-031){ref-type="fig"}). Within the group of controlled studies using parallel designs, active interventions were superior to placebo (differences in means: 0.43 \[0.36--0.49\]), with less of a difference observed in cohorts treated for constipation (0.36 \[0.29--0.43\]) compared to those with IBS-C (0.56 \[0.45--0.66\]; Q = 9.0; *P* = 0.009; [Fig. 3B](#f3-jnm-22-031){ref-type="fig"}). An assessment for potential bias in reporting treatment effects did not show significant skewing of results with Eggert's regression intercept being 2.61 (SEM: 3.65; *P* = 0.247).

Pain Intensity Ratings
----------------------

Baseline pain levels were in the moderate range, with an intensity rating of 2.12 \[1.81--2.42\] based on a 5-point rating scale ([Fig. 4A](#f4-jnm-22-031){ref-type="fig"}). While the funnel plot did not demonstrate asymmetry ([Fig. 4B](#f4-jnm-22-031){ref-type="fig"}), the intercept of Egger's regression suggested publication bias (10.46 (SEM: 1.98), *P* \< 0.001). Treatments reduced pain ratings in patients with chronic constipation and IBS-C by 0.58 \[0.49--0.68\] points ([Fig. 5A and 5B](#f5-jnm-22-031){ref-type="fig"}). Only 2 treatments (one with colchicine, the other with tegaserod) were associated with increased pain ratings in 2 small studies.[@b27-jnm-22-031],[@b40-jnm-22-031] One additional study reported slightly higher rates of discomfort in a placebo-treated cohort.[@b48-jnm-22-031] When we limited the comparisons to controlled trials with parallel designs, we found that active interventions were superior to placebos (difference of 0.26 \[0.20--0.32\]), with significantly lower pain reductions observed in cohorts with constipation (0.14 \[0.07--0.21\]) compared with IBS-C (0.53 \[0.43--0.64\]; Q = 39.2; *P* = 0.001). [Figure 5C](#f5-jnm-22-031){ref-type="fig"} demonstrates that these studies did not show obvious skewing, even though the intercept of Egger's regression with −2.15 (SEM: 1.07; *P* = 0.025) indicated publication bias.

Comparison Between Trials in Cohorts with Constipation and Irritable Bowel Syndrome with Constipation
-----------------------------------------------------------------------------------------------------

Cohorts with chronic constipation (2.00 \[1.62--2.38\]) had a lower baseline weekly defecation frequency than those with IBS-C (2.77 \[2.40--3.14\]; Q = 8.18, *P* = 0.002). Treatment effects expressed in increases in weekly bowel frequency differed significantly differences between cohorts with constipation (active treatment: 3.49 \[2.79--4.20\]; placebo: 1.73 \[1.02--2.43\]) and IBS-C (active intervention: 1.74 \[1.13--2.35\]; placebo: 1.01 \[0.72--1.31\]; Q = 13.5, *P* \< 0.001). Cohorts with IBS-C patients tended to describe slightly higher baseline pain ratings (2.35 \[2.10--2.60\]) than those with constipation (2.02 \[1.63--2.42\]), but this difference was not statistically significant (Q = 1.91; *P* = 0.167). Therapies led to comparable decreases in pain ratings in studies focusing on constipation (0.53 \[0.41--0.65\]; active treatment: 0.70 \[0.40--0.55\]; placebo: 0.49 \[0.26--0.71\]) and IBS-C (0.68 \[0.51--0.84\]; Q = 2.0, *P* = 0.158; active treatment: 0.77 \[0.52--1.03\]; placebo: 0.56 \[0.32--0.81\]).

Relationship Between Bowel Movement Frequency and Abdominal Pain
----------------------------------------------------------------

We hypothesized that laxation would improve abdominal pain in those with chronic constipation and IBS-C independent of the mechanism of the laxative agent. To test this hypothesis, we used meta-regression techniques applied to the aggregate data on baseline and post-treatment assessments of weekly BM frequency and abdominal pain, which showed that increases in weekly BM frequency were significantly correlated with improvements in pain scores (Q = 13.8, *P* \< 0.001; [Fig. 6](#f6-jnm-22-031){ref-type="fig"}). These data were taken from studies using multiple different therapeutic strategies, including conventional laxatives; in addition, the distribution of data obtained in these studies does show distinct clustering of tegaserod, lubiprostone and linaclotide, agents with presumably specific advantages due to their effects of abdominal discomfort. Thus, this analysis supports the underlying hypothesis that improvement in abdominal pain often accompanies laxation. Considering the potential skewing of data through prospectively designed cohort studies without random design, we repeated the analysis after excluding these studies. Results remained unchanged with meta-regression showing a significant correlation between changes bowel frequency and pain relief ([Supplementary Figure](#s1-jnm-22-031){ref-type="supplementary-material"}).

Analysis of Studies with Dichotomous Endpoints
----------------------------------------------

For our secondary analysis, we reviewed studies with dichotomous endpoints that provided enough information to allow for meta-regression analysis. Thirteen publications (9 constipation, 4 IBS-C) defined response rates based on changes in bowel patterns or global relief of symptoms for IBS-C, and provided information about associated changes in pain intensity ([Table 2](#t2-jnm-22-031){ref-type="table"}). We entered reported data for each subgroup within a trial and found similar response rates for studies of constipation (active intervention: 30.1% \[24.6--36.1\]; placebo: 11.7% \[7.4--18.0\]) and IBS-C (active interventions: 27.2% \[16.2--41.9\], Q = 0.29, *P* = 0.591; placebo: 23.5% \[13.5--27.6\]; Q = 3.8; *P* = 0.051). Aggregate response rates as defined by increased BM frequency significantly correlated with changes in pain ratings in the meta-regression analysis (Q-6.32; *P* \< 0.05; [Fig. 7](#f7-jnm-22-031){ref-type="fig"}), consistent with our hypothesized relationship between increased BM frequency and reductions in abdominal pain.

Discussion
==========

Considering the recent emphasis on pain relief as a specific benefit of linaclotide's mechanism of action,[@b10-jnm-22-031],[@b21-jnm-22-031],[@b54-jnm-22-031] we sought to determine whether there is a general relationship between improvements in bowel frequency and decreases in abdominal pain in patients with constipation or IBS-C. Our systematic analysis of controlled and cohort studies confirms that effective laxation correlates with improved pain ratings in patients with constipation or IBS-C, an effect that is not limited to a small number of agents with a specific mechanism. The meta-regression analysis demonstrates a correlation between the increase in weekly BM frequency and reductions in abdominal pain, which does not only support the role of constipation as a contributor to abdominal discomfort, but also suggests that specific visceral analgesic properties are not needed to improve discomfort associated with constipation.

Based largely on their impact on abdominal pain, the recently introduced pro-secretory agents (lubiprostone and linaclotide) were approved in the United States not only for the treatment of chronic constipation, but also specifically for the management of IBS-C, with marketing campaigns emphasizing their presumably unique benefits related to pain relief.[@b16-jnm-22-031]--[@b18-jnm-22-031] In the case of linaclotide, preclinical mechanistic studies supported the clinical data and suggested a possible specific analgesic effect. These investigations, which were previously also conducted with tegaserod, assessed acute responses to colorectal distension or stretch in normal subjects or animals.[@b19-jnm-22-031]--[@b21-jnm-22-031] Similar experiments did not reveal effects on sensory function with lubiprostone.[@b22-jnm-22-031] Despite the different impact on colorectal sensatory mechanisms,[@b19-jnm-22-031],[@b21-jnm-22-031]--[@b23-jnm-22-031] linaclotide, lubiprostone and tegaserod similarly alleviated chronic pain ratings in IBS-C and constipation.[@b9-jnm-22-031]--[@b11-jnm-22-031],[@b24-jnm-22-031]--[@b26-jnm-22-031]

The relationship between improved bowel patterns and decreased discomfort, as highlighted by our meta-analysis, does not establish an underlying mechanism, but fits into a larger context of past experimental and clinical data. As mentioned above, loperamide reduced bowel frequency in healthy volunteers to a degree sufficient to trigger symptoms consistent with IBS-C.[@b29-jnm-22-031] While few comparative effectiveness analyses of active agents are available, the limited evidence does not support superiority of more recently developed agents with polyethylene glycol (PEG) being either superior or equivalent to tegaserod.[@b27-jnm-22-031],[@b28-jnm-22-031] Similar results were reported for prucalopride, which also targets serotonin receptors. This agent provided no more relief than did PEG at the primary endpoint, and was even inferior at almost all secondary endpoints in a trial of patients with chronic constipation.[@b55-jnm-22-031] This trial was not entered into our analysis, as insufficient quantitative data were provided for baseline pain levels. Finally, a similarly designed clinical trial in children suffering from chronic constipation also demonstrated that the active control (PEG) was more effective than prucalopride.[@b56-jnm-22-031]

Our results do not only raise questions about proposed mechanisms of symptom relief in IBS-C, they also have potential implications for trial design. As there is no firmly established standard of care in constipation or IBS-C, placebo-controlled trials are justifiable. However, recently published guidelines summarized the available evidence and identified strong support for the use of polyethylene glycol or lactulose as effective treatment of chronic constipation.[@b57-jnm-22-031] Both agents are approved and available in the United States and most other countries, come with a substantially lower price tag than the more recently introduced medications, and could thus function as an accepted reference therapy as done in some of the trials involving prucalopride and tegaserod.[@b27-jnm-22-031],[@b28-jnm-22-031],[@b55-jnm-22-031] While not a typical concern in the design of clinical trials, we mentioned drug prices in this context, as the initiation of tegaserod therapy increased overall outpatient costs by more than 30%, raising the fraction of medication-related expenses from 39% to 68%.[@b58-jnm-22-031] Facing such cost concerns, modeling studies for this and other agents concluded that the increased expenses were offset by an improved quality of life and less frequent work absenteeism.[@b59-jnm-22-031]--[@b61-jnm-22-031] However, these conclusions were based upon trials without active intervention in the control group, which is unlikely to occur in clinical practice. Our results and the previously mentioned comparative trials question the validity of these models, as cheaper and effective interventions are available, and as patients seeking medical attention for symptoms of constipation will typically initiate some form of active treatment.

We focused on publications that provided sufficient quantitative details about endpoints for two distinct time points separated by an intervention. Essentially, all studies of prucalopride and several trials using lubiprostone or linaclotide dichotomized responses, or relied on more global ratings of bowel patterns, and were thus not included in our primary analysis. However, an assessment of a subset of these studies that defined treatment response rates based on changes in bowel frequency still showed a similar correlation response rates based on changes in bowel pattern and decreases in abdominal pain ratings. Interestingly, the correlation between aggregate measures of published studies addressing bowel patterns and pain correspond with results of a pilot study, which demonstrated a significant relationship between changes in bowel frequency and pain ratings for individual patients receiving linaclotide for constipation.[@b62-jnm-22-031] The described correlation between improved pain ratings were not only reported in studies of the newly introduced agents for IBS-C,[@b63-jnm-22-031]--[@b67-jnm-22-031] but were also observed in many other trials, which did not meet inclusion criteria for this analysis and examined the effects of interventions ranging from fiber supplements,[@b68-jnm-22-031],[@b69-jnm-22-031] to herbal preparations,[@b70-jnm-22-031] biofeedback,[@b71-jnm-22-031] bisacodyl,[@b72-jnm-22-031] or osmotic laxatives.[@b73-jnm-22-031]--[@b75-jnm-22-031]

While not the focus of this analysis, we noted some statistically significant, but clinically minor, differences in the endpoints between patient cohorts with constipation and IBS-C. Moderate pain levels and low stool frequencies characterized both disorders. Studies typically relied on accepted consensus criteria for functional gastrointestinal disorders when defining their target population. The researchers often included authors who participated in the formulation of these very criteria and/or led trials examining drug effects on constipation or IBS-C in separate studies with similar methodology, at times operationally defining IBS-C by a pain intensity of 3 or more on a 5-point scale.[@b24-jnm-22-031],[@b25-jnm-22-031],[@b63-jnm-22-031],[@b76-jnm-22-031]--[@b78-jnm-22-031] We recognize that other factors, such as pain frequency or impact on quality of life, were not measured and may define differences in those with constipation compared to IBS-C. While our meta-analysis cannot truly address conceptual issues about disease mechanisms or manifestations, the findings are consistent with prospective cohort studies that show a substantial overlap between constipation and IBS-C.[@b1-jnm-22-031],[@b3-jnm-22-031],[@b4-jnm-22-031] Prospective studies will have to determine whether and to what degree these diseases are truly distinct or whether they primarily differ based on a potentially shifting focus and emphasis on symptoms associated with constipation.

Despite our relatively stringent inclusion criteria, the detailed definitions and assessments of endpoints differed among the studies entered into our analysis. Most importantly, the predefined assessment of bowel patterns as a simple, spontaneous, or complete spontaneous BM frequency significantly affected results related to defecation. In addition, effects of interventions were assessed over a wide range of time periods, ranging from 4 weeks to more than 12 months. Differences in trial design, recruitment strategies, sex distribution, ethnic background, and interventions further add to the variability. Overall changes in pain intensity ratings were around 25%, which raises questions about the true relevance of changes observed. Prior studies concluded that decreases in pain severity by about 30% are indeed clinically meaningful.[@b79-jnm-22-031] Considering the role of pain in defining overall improvement and the reported response rates of about 30%, responders likely experienced more significant relief than indicated by the averaged results. Finally, we did not restrict our assessment to controlled trials and included small cohort studies, which described skewed patient populations with more severe disease that were selected for surgical therapy. However, results remained significant even when these cohorts were excluded ([Supplementary Figure](#s1-jnm-22-031){ref-type="supplementary-material"}).

In conclusion, our systematic analysis confirms that effective treatment of constipation also improves pain and discomfort without the need for specific visceral analgesic properties. Considering the substantial concerns about healthcare costs and the long term financial impact of medical therapies for chronic conditions, comparative effectiveness analyses and appropriately designed assessments of the indirect economic impact are needed to truly define the potential advantage of newer and more costly treatments for patients with chronic constipation and IBS-C.

Supplementary Data
==================

Note: To access the [supplementary figure](#s1-jnm-22-031){ref-type="supplementary-material"} mentioned in this article, visit the online version of *Journal of Neurogastroenterology and Motility* at <http://www.jnmjournal.org/>, and at <http://dx.doi.org/10.5056/jnm15171>.
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![Flow chart documenting the results of our search strategy.](jnm-22-031f1){#f1-jnm-22-031}

![Forest plot showing weekly bowel frequencies reported for the different cohorts included in this analysis. (A) The data are grouped based on the underlying diagnosis, with the circled symbols showing the mean results with 95% confidence interval. (B) Separates findings based on the endpoint chosen. (C) Shows the funnel plot for baseline bowel frequencies. Study data include results for active treatment and placebo. IBS, irritable bowel syndrome; SBM/ W, spontaneous bowel movements per week; CSBM/W, complete spontaneous bowel movements per week; BM/W, bowel movements per week.](jnm-22-031f2){#f2-jnm-22-031}

![Forest plot showing treatment-induced increases in bowel frequency for active interventions (A) or placebo groups (B). (C) Shows the funnel plot for changes in bowel frequencies. IBS, irritable bowel syndrome; BM, bowel movement.](jnm-22-031f3){#f3-jnm-22-031}

![Forest plot baseline pain ratings (A) with grouping based on constipation or irritable bowel syndrome (IBS) with constipation. (B) Shows the funnel plot for baseline pain ratings.](jnm-22-031f4){#f4-jnm-22-031}

![Forest plot showing treatment-induced decreases in pain ratings for active interventions (A) or placebo groups (B), with grouping based on constipation or irritable bowel syndrome (IBS) with constipation. (C) Shows the funnel plot for changes in bowel frequencies.](jnm-22-031f5){#f5-jnm-22-031}

![Meta-regression showing the correlation between changes in bowel frequency and pain ratings. Study arms using agents with presumably relevant benefit on pain ratings are marked specifically (linaclotide: black; lubiprostone: grey; tegaserod: hatched). Symbol size is proportional to the relative weight in the analysis.](jnm-22-031f6){#f6-jnm-22-031}

![Meta-analysis of studies with dichotomizing assessment of treatment effects demonstrating the correlation between changes in pain rating and response rates based on change in bowel patterns. Study arms using agents with presumably relevant benefit on pain ratings are marked specifically (linaclotide: black; lubiprostone: grey; tegaserod: hatched). Symbol size is proportional to the relative weight in the analysis. BM/W, bowel movements per week.](jnm-22-031f7){#f7-jnm-22-031}

###### 

Studies Included in the Analysis

  Sample (n)     Design   Intervention               Allocation   Analysis   Drop-out   Endpoints    Duration (weeks)   Reference
  -------------- -------- -------------------------- ------------ ---------- ---------- ------------ ------------------ -------------------
  Constipation                                                                                                          
   22            COD      Bran                       NA           ITT                   BM/W         4                  [@b32-jnm-22-031]
                          Placebo                                                       NRS 0--3                        
   237           RCT      Lubiprostone               1:1          ITT        A: 20      SBM/W        4                  [@b24-jnm-22-031]
                          Placebo                                            C: 10      NRS 0--4                        
   130           RCT      PEG & Electrolytes         1:1          ITT        A: 30      BM/W         4                  [@b33-jnm-22-031]
   137                    PEG                                                C: 25      NRS 1--4                        
   120           RCT      Hemp                       1:1          ITT        A: 18      BM/W         8                  [@b34-jnm-22-031]
                          Placebo                                            C: 13      NRS 0--6                        
   109           Cohort   Biofeedback                A: 55        NA          NA        BM/W         51                 [@b35-jnm-22-031]
                          Laxatives                  C: 54                              NRS 0--4                        
   66            RCT      Probiotic                  1:1          ITT        A: 2       SBM/W        4                  [@b36-jnm-22-031]
                          Placebo                                            C: 4       NRS 0--4                        
   242           RCT      Lubiprostone               1:1          ITT        A: 9       SBM/W        4                  [@b11-jnm-22-031]
                          Placebo                                            C: 5       NRS 0--4                        
   1348          RCT      Tegaserod (2 dosages)      1:1:1        ITT        A: 77      SBM/W        12                 [@b25-jnm-22-031]
                          Placebo                                             67        NRS 0--4                        
                                                                             C: 86                                      
   1264          RCT      Tegaserod (2 dosages)      1:1:1        ITT        A: 72      SBM/W        12                 [@b26-jnm-22-031]
                          Placebo                                             70        NRS 0--4                        
                                                                             C: 74                                      
   45            Cohort   Sacral Stimulator          NA           NA                    SBM/W        4                  [@b37-jnm-22-031]
                                                                                        VAS                             
   16            COD      Colchicine                 NA           ITT                   BM/W         4                  [@b40-jnm-22-031]
                          Placebo                                                       VAS                             
   7             Cohort   Colchicine                 NA           NA                    SBM/W        4                  [@b38-jnm-22-031]
                                                                                        NRS 0--10                       
   13            Cohort   Colectomy                  NA           NA                    SBM/W        NA                 [@b39-jnm-22-031]
                                                                                        NRS 0--10                       
   82            RCT      Cisapride                  1:1          ITT        A: 6       CSBM/W       12                 [@b41-jnm-22-031]
                          Placebo                                            C: 6       VAS                             
   32            RCT      Mosparide                  Unclear      PP          20        BM/w         8                  [@b53-jnm-22-031]
                          Domperidone                                         12        NRS 0--6                        
   43            OL       Na Phosphate (2 dosages)   Unclear      PP          18        BM/W         4                  [@b52-jnm-22-031]
                                                                              25        NRS (0--4)                      
  IBS                                                                                                                   
   34            RCT      Probiotic                  1:1          ITT                   BM/W         4                  [@b44-jnm-22-031]
                          Placebo                                                       NRS 1--6                        
   42            RCT      PEG                        1:1          ITT                   BM/W         4                  [@b45-jnm-22-031]
                          Placebo                                                       VAS                             
   139           RCT      PEG                        1:1          ITT        A: 7       SBM/W        4                  [@b46-jnm-22-031]
                          Placebo                                            C: 8       NRS 0--4                        
   22            RCT      Tegaserod                  1:1          ITT                   BM/W         4                  [@b27-jnm-22-031]
                          PEG                                                           NRS 0--3                        
   193           RCT      Lubiprostone (3 dosages)   1:1:1:1      ITT        A: 10      SBM/W        12                 [@b12-jnm-22-031]
                                                                              16        NRS 0--4                        
                          Placebo                                             15                                        
                                                                             C: 7                                       
   803           RCT      Linaclotide                1:1          ITT        A: 94      SBM/W        12                 [@b47-jnm-22-031]
                          Placebo                                            C: 62      NSR 0--10                       
   179           RCT      Probiotic                  1:1          ITT                   SBM/W        4                  [@b48-jnm-22-031]
                          Placebo                                                       NRS 0--5                        
   41            RCT      Probiotic                  Unclear      ITT        A: 19      BM/W         12                 [@b43-jnm-22-031]
                          Placebo                                            C: 22      VAS                             
   212           OL       Tegaserod                               PP                    BM/W         12                 [@b51-jnm-22-031]
                                                                                        NRS 0--4                        
   90            RCT      Herbals                    1:1          ITT                   BM/W         12                 [@b49-jnm-22-031]
                          Placebo                                                       NRS 1--3                        
   69            RCT      Cisapride                  1:1          ITT        A: 4       BM/W         12                 [@b50-jnm-22-031]
                          Placebo                                            C: 5       NRS 0--3                        

COD, cross over design; NA, not applicable; ITT, intention to treat; BM/W, bowel movements per week; NRS, numeric rating scale (given with range); RCT, randomized controlled trial; A, active therapy; SBM/W, spontaneous bowel movements per week; C, control group; PEG, polyethylene glycol; CSBM/W, complete spontaneous bowel movements per week; VAS, visual analog scale; OL, open label trial; PP, per protocol; IBS, irritable bowel syndrome.

The endpoints are given for bowel frequency (top) and pain intensity (bottom).

###### 

Studies with Dichotomized Endpoints Related to Bowel Patterns

  Sample (n)     Design   Intervention                        Allocation   Analysis   Drop-out   Endpoints           Duration (weeks)   Reference
  -------------- -------- ----------------------------------- ------------ ---------- ---------- ------------------- ------------------ -------------------
  Constipation                                                                                                                          
   713           RCT      Prucalopride (2 dosages)            1:1:1        ITT        A 29       ≥3 CSBM/W           12                 [@b64-jnm-22-031]
                                                                                       54        PAC-Sym                                
                          Placebo                                                     C 33                                              
   1272          RCT      Linaclotide (2 trials, 2 dosages)   1:1:1        ITT        A 71       ≥3 CSBM/W           12                 [@b80-jnm-22-031]
                                                                                       76        NRS (0--5)                             
                          Placebo                                                     C 56                                              
   307           RCT      Linaclotide (4 dosages)             4:1          ITT        A 5        ≥3 CSBM/W           4                  [@b9-jnm-22-031]
                                                                                       6         NRS (0--5)                             
                                                                                       4                                                
                                                                                       12                                               
                          Placebo                                                     C 8                                               
   620           RCT      Prucalopride (2 dosages)            1:1:1        ITT        A 27       ≥3 CSBM/W           12                 [@b63-jnm-22-031]
                                                                                       31        PAC-Sym                                
                          Placebo                                                     C 23                                              
   641           RCT      Prucalopride (2 dosages)            1:1:1        ITT        A 20       ≥3 CSBM/W           12                 [@b65-jnm-22-031]
                                                                                       24        PAC-Sym                                
                          Placebo                                                     C 30                                              
   501           RCT      Prucalopride                        1:1          ITT        A 23       ≥3 CSBM/W           12                 [@b81-jnm-22-031]
                          Placebo                                                     C 18       PAC-Sym                                
   322           RCT      Tegaserod                           1:1          ITT        A 28       Increase of ≥1      12                 [@b82-jnm-22-031]
                          Placebo                                                     P 25       CSBM/W                                 
                                                                                                 NRS (0--4)                             
   70            RCT      PEG                                 1:1          ITT        A 10       BM/W                20                 [@b83-jnm-22-031]
                          Placebo                                                     P 4        NRS (0--4)                             
   237           RCT      PEG                                 1:1          ITT        A 14       BM/W                12                 [@b28-jnm-22-031]
                          Tegaserod                                                   A 20       PAC-Sym                                
  IBS                                                                                                                                   
   804           RCT      Linaclotide                         1:1          ITT        A 108      ≥3 CSBM/W           12                 [@b67-jnm-22-031]
                          Placebo                                                     C 98                                              
   419           RCT      Linaclotide (4 dosages)             4:1          ITT        A 16       ≥3 CSBM/W           12                 [@b10-jnm-22-031]
                                                                                       15        (75% of the time)                      
                                                                                       14        NRS (0--5)                             
                                                                                       18                                               
                          Placebo                                                     C 20                                              
   1154          RCT      Lubiprostone                        2:1          ITT        A 183      SBM/W               12                 [@b77-jnm-22-031]
                          Placebo                                                     P 99       NRS (0--4)                             
   1519          RCT      Tegaserod                           1:1          ITT        A 158      BM/W                12                 [@b84-jnm-22-031]
                          Placebo                                                     P 161      NRS (0--4)                             

RCT, randomized controlled trial; ITT, intention to treat; A, active therapy; CSBM/W, complete spontaneous bowel movements per week; C, control group; PAC-Sym, Patient Assessment of Constipation Symptoms; NRS, numeric rating scale (given with range); PEG, polyethylene glycol; BM/W, bowel movements per week; IBS, irritable bowel syndrome; SBM/W, spontaneous bowel movements per week.

The endpoints are given for bowel frequency (top) and change in pain intensity (bottom).
